Stevenage Bioscience Catalyst (SBC) has launched an accelerator programme to give start-ups working on data-enabled drug discovery, genomics and advanced therapies the skills they need to get potential new drugs and therapies to market more quickly.
The programme, which is offered at no cost, runs from May and is aimed at supporting start-up companies working to discover new drugs and therapies. Those selected will take part in an 18-week programme giving them the opportunity to network and learn from experts in the pharmaceutical and biotech industries. Start-ups will be able to build their…
Cambridge, UK, 01 March 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced the promotion of Dr Neil Torbett to Chief Executive Officer, with immediate effect. Dr Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board. Dr Torbett joined PhoreMost as Chief Business Officer in January 2017 and was promoted to Chief Operating Officer in 2020, holding responsibility for all operational, scientific and commercial activities. During…
AMSBIO reports how researchers at the Washington University School of Medicine (St. Louis, USA) have used their 10E4 Heparan Sulfate (HS) antibody in pioneering obesity research to quantify the role of HS in the process of intercellular mitochondria transfer to macrophages.
In recent published research**, researchers from the Brestoff and Teitelbaum Labs demonstrated that adipose-tissue resident macrophages acquire mitochondria from adjacent adipocytes using HS. This process occurs in healthy conditions but is impaired in obesity. Further they have shown that genetic disruption of…
Cambridge, UK, 28th February 2022: Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village.
Aiming to develop safer cell and gene therapies by assessing the stability of the genome, Broken String Biosciences is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that are safer by design. Its core technology, INDUCE-seq™, is a DNA break mapping technology that enables companies developing cell and gene therapies to assess the specificity of…
• Funding will support recruitment, commercial partnerships, and further development of Semarion’s SemaCyte cell assaying platform, which turns adherent cells into liquid reagents to enable novel drug screening methodologies
• Investors include Parkwalk Advisors, University of Cambridge Seed Funds, Martlet Capital, and angel investors
Cambridge, UK, 22 February 2022: Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced today that it has closed a £2.14 million GBP…
We are excited to announce the launch of our new course, providing the training and examination required to become a IRCA Accredited GMP Pharmaceutical Quality System Lead Auditor.
Following on from the successful PR330 IRCA QMS Pharmaceutical Suppliers ISO9001/PQG Lead Auditor course, RSSL is launching the new GMP Pharmaceutical Quality Systems (GMP/ICHQ10) Lead Auditor Course from Spring 2022!
“Auditing is an in-demand skillset for today’s pharmaceutical professional”, says Kasia Szymaniec, Head of Training at RSSL. “As well as formal training on international auditing standards and…
BioIVT will showcase its complete range of products and services for cell and gene therapy and immuno-oncology drug developers
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting an open house from 7-9 pm on February 23. Light hors d'oeuvres will be served in a COVID-19 compliant setting at the Scale Space venue at 58 Wood Lane, London W12 7RZ. Then, BioIVT staff will give guided tours of the company’s new laboratories and blood donor center so researchers can see how the company’s high quality…
Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has made a key business development appointment in support of its ambitious growth plans.
Haroon Allybacus joins Cellomatics as Senior Business Development Manager. With more than 20 years’ experience in the pharmaceutical, contract research and ‘omics’ industries, Haroon has held numerous business development roles, most recently as European Account Manager at Human Metabolome Technologies, the global provider of next generation metabolomics. With a Chemistry with Management Science BSc Hons and an MBA in…
OXFORD, UK February 21, 2022 – PrecisionLife Limited, a global techbio company driving precision medicine in chronic diseases with drug discovery, clinical development, and healthcare solutions based on its unique insights into disease biology, announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the Company’s UK headquarters in Oxfordshire, UK.Dr Stubberfield brings over three decades experience in leading drug discovery research in the life sciences industry. At PrecisionLife he will be responsible for developing the Company’s pipeline of…
Air Products is proud to announce that it has been awarded Medical Device Regulation (MDR) EC Mark certificate for Medical Device liquid nitrogen for the UK.
Do I need MDR liquid nitrogen?
It depends on your application. If it involves the storage of human tissue samples the chances are that you do. This includes any applications that use liquid nitrogen for preserving blood and bone marrow cells, sperm, ova, early embryos, and, in the microbiology laboratory, a variety of microorganisms (bacteria, fungi, etc) Another application that requires MDR liquid nitrogen is cryotherapy, which refers…